达比加群与华法林治疗后血栓形成后综合征的长期随访
该研究对RE-COVER三期研究中加拿大、挪威和瑞典的患者进行横断面长期随访,比较达比加群与华法林对血栓形成后综合征(PTS)、复发静脉血栓栓塞(VTE)及健康相关生活质量(HRQoL)的影响。共纳入349例患者,平均距索引事件8.7年,结果显示两组PTS患病率、复发VTE及HRQoL均无差异。
要点
- 深静脉血栓(DVT)患者PTS患病率为63%,单纯肺栓塞(PE)患者为46%。
- 达比加群与华法林组PTS粗比值比:DVT后1.1(95%CI 0.6-1.8),单纯PE后1.2(95%CI 0.5-2.6)。
- 两组复发VTE患病率均为21%,HRQoL评分无差异。
核心结论
- 在长期横断面随访中,达比加群与华法林治疗患者的PTS患病率、复发VTE及HRQoL相似。
研究设计与样本
- RE-COVER三期研究中加拿大、挪威和瑞典患者的横断面随访研究,共纳入349例,达比加群166例、华法林183例。
- DVT(±PE)为索引事件255例,单纯PE为94例;距索引事件平均8.7年(标准差1.4)。
- PTS采用患者报告的Villalta量表(PRV)评估,HRQoL采用EQ-5D和VEINES-QOL/Sym评估。
主要发现
- DVT患者PTS患病率为63%,单纯PE患者为46%。
- 达比加群相比华法林的PTS粗OR:DVT后1.1(95%CI 0.6-1.8),单纯PE后1.2(95%CI 0.5-2.6)。
- 两组复发VTE患病率均为21%,HRQoL评分无差异。
临床怎么用
- 对于急性DVT和/或PE患者,达比加群与华法林在长期PTS及复发VTE风险上未见差异,选择抗凝药时可综合考虑其他因素。
局限性
- 为横断面随访设计,样本仅来自三个国家,PTS采用患者报告量表评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Studies suggest that the direct factor Xa inhibitor rivaroxaban compared to warfarin reduces the risk of post-thrombotic syndrome (PTS) after deep vein thrombosis (DVT), but this has not been evaluated for oral direct thrombin inhibitors. OBJECTIVES: To compare the long-term prevalence of PTS, recurrent venous thromboembolism (VTE), and health-related quality of life (HRQoL) in patients with acute DVT and/or pulmonary embolism (PE), randomized to treatment with dabigatran or warfarin in the phase III RE-COVER studies. METHODS: We conducted a cross-sectional follow-up study of patients randomized in Canada, Norway, and Sweden. PTS was assessed by the patient-reported Villalta scale (PRV) and HRQoL by EQ-5D and VEINES-QOL/Sym. RESULTS: We included 349 patients between December 2015 and November 2018; 166 were treated with dabigatran and 183 with warfarin. DVT (+/- PE) was index event in 255 patients, whereas 94 patients had PE only. Mean time from index event was 8.7 (standard deviation 1.4) years. PTS was diagnosed in 63% of patients with DVT and in 46% of patients with PE only, and did not differ between the treatment groups; the crude odds ratio (OR) for PTS in patients treated with dabigatran compared with warfarin was 1.1 (95% confidence interval [CI] 0.6-1.8) after DVT and 1.2 (95% CI 0.5-2.6) after PE only. The prevalence of recurrent VTE was 21% in both treatment groups. HRQoL scores did not differ between groups. CONCLUSION: In this long-term cross-sectional study, the prevalence of PTS, recurrent VTE, and HRQoL were similar in patients treated with dabigatran and warfarin.
引用
- Wik HS, Kahn SR, Eriksson H, et al. Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients. J Thromb Haemost. 2021. PMID: 34255420. doi:10.1111/jth.15449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。